Minister Should Fess Up On Cuts
Simeon Brown needs to be honest about how much more money he expects Health New Zealand to cut from its budget to get back in the black.
'National has chosen to underfund our health system and expects Health New Zealand to make even more cuts - but won't say how much,' Labour health spokesperson Ayesha Verrall said.
'Health New Zealand, which runs our hospitals and other healthcare services, was already $1.1 billion in the red. Funds needed to deal with a growing population and inflation are instead servicing the deficit.
'In today's scrutiny week hearing, Simeon Brown pretended that all the new money from this year's Budget would go on frontline services, but most of it will be swallowed by Health New Zealand's $1.1 billion deficit.
'New Zealanders deserve to know where their money is going. They also deserve timely, quality care both in the community at their local doctor's office, or in hospital should they need it. Simeon Brown is failing on both points.
'Simeon Brown's refusal to answer basic questions—like how much further he's prepared to slash Health New Zealand's budget, or which parts of the health system are on the chopping block—shows a worrying lack of transparency. What is he hiding from New Zealanders?
'National is making cuts to services New Zealanders rely on and is not even brave enough tell us what they are,' Ayesha Verrall said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
3 hours ago
- RNZ News
Taxpayer to foot the bill for cancer drugs for private patients
Taxpayers will soon begin footing the bill for newly-funded cancer medicines administered in private facilities for 12 months, under the so-called "transitional access" arrangement. Photo: 123RF The government's decision to let private patients have publicly-funded cancer drugs is a waste of taxpayers' money, and could even make wait times worse, the Labour Party is warning. From 1 July, taxpayers will begin covering the cost of newly-funded cancer medicines administered in private facilities for 12 months, under the so-called "transitional access" arrangement. In a testy exchange with the Associate Health Minister David Seymour at Wednesday's health select committee, Labour Party spokesperson Dr Ayesha Verrall pointed out the vast majority of New Zealanders did not have private health insurance. "Wouldn't this money have been better spent on hiring oncologists in the public system so that people can get free care there?" Under the current framework, insurers already picked up the tab for any new medicines that Pharmac funded, so the change did not actually benefit patients in most cases, she said. "So this money that you are spending on this is achieving almost nothing in terms of access, it's just a subsidy for insurers." However, Seymour disagreed, saying one should not underestimate the "inconvenience" of having to shift facilities mid-treatment, and people "should not be disadvantaged by the fact that they have taken precaution of having private insurance". "When you're getting treated for cancer, you just don't want any more problems in your life or inconveniences in your life, you just want to get through it." He dismissed Labour's characterisation of the change as "subsidising private insurers". "Insurers don't have any money other than what's paid to them by the patients," he said. "So ultimately this is also a subsidy for the patients, who are also taxpayers who are entitled to public funding in this country.... "You can always say we could do more if we were prepared to exclude some New Zealanders from care in the public system." "Everyone is entitled to care in the public system," Verrall responded. Private patients who were not covered by insurance would still have to pay "infusion" costs to have the medicines administered. Pharmac chair Paula Bennett said the drug-funding agency had been contacted by patients who were in private care and had insurance before Pharmac started funding more cancer medicines. "One man was eligible for four treatments but actually needed 12 and he was going to have to move into the public system to receive the other eight. "The thought of having to change oncologist just to get access to the extra eight treatments that he desperately needed was incredibly stressful." According to correspondence between officials and the minister's office, which was released to the Labour Party under the Official Information Act, the plan was initially going to be announced in April. Seymour was unable to say why the announcement had not gone ahead as planned. Talking points provided to the minister ahead of the Cabinet discussion on 2 April noted no additional funding was being sought for the proposal, but instead Pharmac would "make some trade-offs within the medicines budget" to fund it. "Numbers of patients that will benefit from transitional access may well be small (likely less than 10 per medicine) but over time this policy will reach patients at a critical time." In a statement to RNZ, Pharmac director strategy, policy, and performance Michael Johnson said the rule change applied "only to newly funded cancer medicines (medicines funded after 1 July 2025). "The number of patients expected to benefit from this change will depend on what cancer treatments are funded in the future. " Labour's Ayesha Verrall said doctors working in the public system feared shifting more resources into the private system would further increase inequities and wait times for patients who could not afford private care. Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
Scoop
5 hours ago
- Scoop
Āti Awa Toa Hauora Partnership Board Welcomes Opportunity To Work With Hauora Māori Advisory Committee
The Āti Awa Toa Hauora Partnership Board welcomes the opportunity to work alongside the Hauora Māori Advisory Committee to strengthen Māori health leadership and outcomes. This follows a weekend announcement by Health Minister Simeon Brown on the Government's plans to amend the Pae Ora Act 2022. 'We support efforts to bring greater clarity and coordination across the system,' says Hikitia Ropata, Chair of the Āti Awa Toa Hauora Partnership Board. 'We see real value in building strong relationships between national bodies and local, whakapapa-based leadership.' 'As an Iwi-Māori Partnership Board, we bring the korowai of our iwi. Together we are grounded in our communities with lived experience, cross-sector relationships and local solutions that are essential to transforming the health system to truly serve all people who live here - those who whakapapa to us and those who call our rohe home.' 'We remain committed to working collaboratively to raise the voices of whānau and track how the health system is performing for Māori in our community.
1News
8 hours ago
- 1News
Medsafe approves sale of melatonin and prescribing magic mushrooms
Relief is on the way for Kiwis struggling with insomnia and treatment-resistant depression, with Medsafe approving the sale of over-the-counter melatonin and the prescription of medicinal psilocybin. Melatonin – used to treat insomnia and jet lag – would be available for purchase in pharmacies without a prescription in due course. The medicine has previously been tightly restricted in New Zealand. Currently, only a handful of melatonin products were approved for people aged over 55. 'Many New Zealanders have asked me why people can buy melatonin overseas but they can't buy it from their local pharmacy. Medsafe has assessed this and decided there's no reason why it shouldn't be available on pharmacy shelves right here at home,' Associate Health Minister David Seymour said. 'In time, adults will be able to buy melatonin directly from a pharmacy with no prescription needed. This is a common sense decision that will make melatonin more accessible in New Zealand than in many other countries and encourage suppliers [to] bring more products to our shelves." ADVERTISEMENT Melatonin would remain prescription-only for children and adolescents, following expert clinical advice to ensure proper oversight when used by younger patients. For the first time in New Zealand, Medsafe has also approved the prescribing of medicinal psilocybin outside of clinical trials, Seymour said. Also known as magic mushrooms, psilocybin was a naturally occurring psychedelic compound found in more than 100 species of mushrooms. While psilocybin would remain as an unapproved medicine, a psychiatrist with prior experience prescribing magic mushrooms in clinical trials has been granted authority to prescribe it to patients with treatment-resistant depression. The prescriptions would be under strict reporting and record-keeping requirements. Seymour said the decision is "huge for people with depression who've tried everything else and are still suffering". "If a doctor believes psilocybin can help, they should have the tools to try." The move brought New Zealand in line with Australia, where "authorised prescribers have been using psilocybin in clinical settings for some time". 'Kiwis shouldn't be left counting sheep or desperate for options when other countries are already using these medicines," Seymour said. "The Government is committed to putting patients first.'
